Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Cephalon |
---|---|
Information provided by: | Cephalon |
ClinicalTrials.gov Identifier: | NCT00236119 |
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type Psoriasis.
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: CEP-701 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe, Recalcitrant, Plaque Type Psoriasis |
Enrollment: | 46 |
Study Start Date: | June 2005 |
Study Completion Date: | October 2007 |
Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients with Severe, Recalcitrant, Plaque Type Psoriasis.
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients are included in the study if all of the following criteria are met:
Exclusion Criteria:
United States, North Carolina | |
Wake Forest University | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Texas | |
Texas Dermatology Rsch Inst | |
Dallas, Texas, United States, 75230 | |
United States, Virginia | |
Viginia Clinical Research | |
Norfolk, Virginia, United States, 23507 |
Study ID Numbers: | C0701/2024/DR/US |
Study First Received: | October 11, 2005 |
Last Updated: | February 21, 2008 |
ClinicalTrials.gov Identifier: | NCT00236119 |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |